Sangamo BioSciences Announces Presentation Of Data For ZFP Therapeutic For Glioblastoma At American Society For Hematology Meeting

SangamoBioSciences, Inc. (Nasdaq: SGMO) announced the presentation ofpositive data in a mouse tumor model from its program to develop a novelcell therapy using its zinc finger DNA-binding protein nuclease (ZFN(TM))technology for treatment of glioblastoma multiforme (GBM), a progressiveand usually fatal brain cancer. The data were presented at the 49th AnnualMeeting of the American Society of Hematology (ASH) by Sangamo’scollaborator Michael C.V. Jensen, M.D. [click link for full article]

More: continued here

Filed under: Cancer on December 11th, 2007